OncoSec reports data showing single cycle of monotherapy TAVO(TM) improve immune responses
OncoSec announced data that suggests treatment with TAVO(TM) (tavokinogene telseplasmid) has the ability to improve immune responses in heavily pretreated, inoperable and locally advanced TNBC by increasing TIL density, increasing effector cytokines, and upregulating immune-related gene expression.
December 11, 2018